hmmm....EBITDA in FY20 & FY21 was ~12m off revenues of 100-105m
FY2022 forecast revenues of 115m (so a ~9% inprovement) but resulting in a reduction in EBITDA ("low single-digit").
Their June strategy presentation indicated (at least for FY21) that EBITDA would be ~10% of revenues and long term (FY24) would improve to 15-20%, but this guidance seems to actually show EBITDA margins reducing.....more spend on R&D and S&M in the short term??
Ann: Gentrack provides updated guidance for FY22, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GTK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.23 |
Change
-0.080(0.86%) |
Mkt cap ! $955.2M | |||
| Open | High | Low | Value | Volume |
| $9.33 | $9.38 | $9.19 | $1.762M | 190.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4318 | $9.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.26 | 489 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| GTK (ASX) Chart |